Cancer reported in nine Zolgensma recipients is drawing fresh attention to a concern that gene therapy has faced for years. The FDA is investigating the cases, but says Zolgensma’s benefits still outweigh the possible risks when used as approved. For families and companies developing similar medicines, a question remains: how much can these cases say about a risk that is still uncertain?
Key Points
- According to Novartis, Zolgensma has been given to 6,000 people.
- Two cancer cases had evidence of the viral carrier becoming integrated into patients’ DNA.
- Zolgensma brought in $1.1 billion during 2026’s opening nine months.
Zolgensma’s Benefits and the Safety Concerns
Zolgensma has approval as a gene replacement treatment for SMA, which is a genetic condition that leaves patients short of a protein called SMN. Before the newer drugs became available, many young children died from severe SMA, and older patients with less severe disease had disabilities for the rest of their lives. Zolgensma has shown that it can change the course of SMA, and treatments made by Biogen and Roche, as well as Scholar Rock, have shown that ability too.
AveXis developed Zolgensma, and Novartis later bought AveXis. Zolgensma delivers a gene using a virus called AAV, which carries the instructions cells need to produce SMN. Researchers have worried for years about whether AAV could enter patients’ DNA and possibly help cause cancer. Animal research stretching back decades showed that AAVs could become part of the genetic material of certain animals. Those concerns drew more attention in 2021, when someone who received a UniQure gene treatment was diagnosed with liver cancer.
The treatment from UniQure was later ruled out as the cause. But researchers still sought closer monitoring for cancer risk during an FDA meeting in 2021.
Patients now have evidence that treatment helps, and they also face a significant question about safety. The cancer reports need attention. But a cancer diagnosis after someone receives Zolgensma does not, by itself, establish that Zolgensma caused it, and saying the treatment caused all nine cancers would claim more than the findings establish.
Previous case reports documented cancer among people treated with Zolgensma. Neither report established a definite connection between the cancer and Zolgensma.
| Year reported | Patients described | What was found |
|---|---|---|
| 2023 | People given Zolgensma | A treatment link was not established |
| 2025 | People given Zolgensma | A treatment link was not established |
FDA Examines Cancer Reports but Still Finds Benefits Greater Than Risks
Novartis’ latest disclosure adds seven cases to those previously reported. In two cases, DNA integration was found, and Novartis said both patients received treatment and remain under monitoring.
On Nov. 6, the FDA disclosed its investigation into the cancer cases. Tumors were found in the kidney, in both central and peripheral parts of the nervous system, and within or near the spine. According to the FDA, three tumors were linked to GLH1, which is a gene that can cause cancer. In the two cases pointing to Zolgensma, the gene delivered by Zolgensma was expressed near GLH1.
The cancer risk also applies to Itvisma, the FDA said. Itvisma is given intrathecally, which means delivery into the fluid around the spinal cord. For both Itvisma and Zolgensma, the FDA continues to find that benefits are greater than possible risks for approved uses, and the FDA is considering whether to take regulatory action. Tumors from three out of the nine patients have undergone testing, according to Cure SMA. One case does not appear connected to Zolgensma. Cure SMA has contacted Novartis and is reviewing the available information about safety with scientific and clinical experts, and Cure SMA remains in touch with regulators and clinical partners.
SMA Europe said the reports are worrying for families, both those whose children received Zolgensma already and those weighing treatment now. SMA Europe urged Novartis to explain the findings in terms families can understand, including what is known and where uncertainty remains. Families need to understand what the reports might mean for people treated previously, and whether any further monitoring or other action is advised.
Hospitals caring for these patients still face an unanswered practical question about how monitoring should be done.
The FDA’s assessment that treatment benefits remain greater than risks gives families important context. But the assessment does not yet make clear whether the findings could lead to changes in patients’ follow-up care.
Zolgensma Sales And Questions For Gene Therapy
Zolgensma was first approved for children who had not yet turned two, and the price for Zolgensma was $2 million-plus. The FDA investigated the data behind the approval. Novartis was eventually cleared of wrongdoing, and a later approval allowed Zolgensma to be used in more people.
Zolgensma brought in over $1 billion last year, which put Zolgensma ahead of every other gene replacement therapy in sales. Some other treatments have struggled to find a place in the market.
| Drug | Condition treated | Reported status |
|---|---|---|
| Zolgensma | SMA | Leads gene replacement therapies in sales |
| Itvisma | SMA | Benefits outweigh possible risks, FDA says |
| Elevidys | Duchenne muscular dystrophy | Struggled with sales despite high expectations |
| Roctavian | Hemophilia | Withdrawn because uptake was slow |
Drug developers also have questions to address about the evidence concerning a tool used to deliver gene therapy, and about what the evidence could mean for confidence in the treatments those companies are working on. The reports of cancer could bring more scrutiny to products besides Zolgensma. But the findings about Zolgensma do not show whether other treatments carry a risk of cancer.
The benefits Zolgensma has provided for patients, and the sales Zolgensma has recorded, make the investigation especially important.
What happens next will depend in part on the results of tumor testing and on what turns up as monitoring continues. It will also depend on whether the FDA decides any regulatory changes are needed.
